In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Renewed DES Safety Debate Creates Second Generation Mover Advantage

Executive Summary

Recent clinical trial analysis has revived the debate over the safety of drug-eluting stents (DES), creating the possibility that safety, rather than efficacy, may turn out to be a differentiating factor for companies developing next-generation products.
Advertisement

Related Content

TCT Debates Cardiology's "Climate of Calamity"
COURAGE Trial: Bad News Again for Stents at ACC, Or Is It?
AHA Wrap-Up: Studies Emphasize Improved Outcomes, Cost Effectiveness
Industry Perspective - The Medtech Industry: A Look Back at 2006
Business & Technology Briefs (01/2007)
At TCT, DES Use and Safety Concerns: Irrational Exuberance or Irrational Anxiety?
TCT Highlights: Late Stent Thrombosis Controversy Continues
Turning Around Medtronic Vascular
Turning Around Medtronic Vascular
Conor: An Outsider Delivers Drug-Stents' Next Generation

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel